{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '119', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'OS follows an exponential distribution, with a median of 16.7 months for the control group.', 'Enrollment period is approximately 21.7 months.', 'Annual drop-out rate is 20% and 2% for PFS and OS, respectively.', 'Follow-up period is approximately 8.8 and 18.5 months for PFS and OS, respectively, after', 'the last participant is randomized.', 'The sample size and power calculations were performed in R (package \"gsDesign\") and', 'EAST 6.4.', 'Extension Study in China', 'As of amendment 007-06, enrollment in the Extension Study in China has been stopped.', 'In order to evaluate the consistency of efficacy and safety in the subpopulation in China', 'compared with the global population, following completion of global study enrollment,', 'participants in China will continue to be randomized in a 1:1 ratio into the pembrolizumab +', 'lenvatinib arm and pembrolizumab + placebo arm until the planned sample size of', 'approximately 120 participants in China is reached. Participants in China randomized after', 'completion of enrollment in the global study will not be included in the analysis of the global', 'study.', '9.10', 'Subgroup Analyses', 'To determine whether the treatment effect is consistent across various subgroups, the', 'between-group treatment effect for OS, PFS, and OR (with a nominal 95% CI) will be', 'estimated and plotted by treatment group within each category of the following subgroup', 'variables:', 'Geographic region (East Asia, non-East Asia)', 'ECOG performance status (0,1)', 'Predominant tumor histology (squamous, nonsquamous)', 'TPS (1%-49%, 50%)', 'Age category (<65, 265 years)', 'Sex (female, male)', 'Race (white, nonwhite)', 'Smoking status (never, former/current smoker)', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '120', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Brain metastasis at baseline (presence, absence)', 'Liver metastasis at baseline (presence, absence)', 'The consistency of the treatment effect will be assessed using descriptive statistics for each', 'category of the subgroup variables listed above. If the number of participants in a category of', 'a subgroup variable is less than 10% of the ITT population, the subgroup analysis will not be', 'performed for this category of the subgroup variable, and this subgroup variable will not be', 'displayed in the forest plot. The subgroup analyses for PFS and OS will be conducted using', 'unstratified Cox model, and the subgroup analyses for OR will be conducted using', 'unstratified Miettinen and Nurminen method.', '9.11 Compliance (Medication Adherence)', 'Drug accountability data for study intervention will be collected during the study. Any', 'deviation from protocol-directed administration will be reported.', '9.12', 'Extent of Exposure', 'Extent of exposure for a participant is defined as number of cycles in which the participant', 'receives the study intervention. Summary statistics will be provided on extent of exposure for', 'the APaT population.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '121', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10 SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '10.1', 'Appendix 1: Regulatory, Ethical, and Study Oversight Considerations', '10.1.1', 'Code of Conduct for Clinical Trials', 'Merk Sharp and Dohme Corp., a subsidiary of Merk & Co., Inc. (MSD)', 'Code of Conduct for Interventional Clinical Trials', 'I. Introduction', 'A. Purpose', 'MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our', 'products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials', 'in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the', 'overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted', 'in compliance with local and/or national regulations (including all applicable data protection laws and', 'regulations), and International Council for Harmonisation Good Clinical Practice (ICH-GCP), and also in', 'accordance with the ethical principles that have their origin in the Declaration of Helsinki.', 'B. Scope', 'Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by', 'MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations,', 'collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or', 'which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the', 'full control of MSD.', 'II. Scientific Issues', 'A. Trial Conduct', '1. Trial Design', 'Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety,', 'efficacy, and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products.', 'Alternatively, MSD may conduct outcomes research trials, trials to assess or validate various endpoint', 'measures, or trials to determine patient preferences, etc.', 'The design (ie, participant population, duration, statistical power) must be adequate to address the specific', 'purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where', 'applicable, third parties. Participants must meet protocol entry criteria to be enrolled in the trial.', '2. Site Selection', 'MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of', 'facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial', 'initiation, sites are evaluated by MSD personnel to assess the ability to successfully conduct the trial.', '3. Site Monitoring/Scientific Integrity', 'Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice', '(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus', 'source documentation according to standard operating procedures. Per MSD policies and procedures, if', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}